XML 115 R102.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Narrative) (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2023
EUR (€)
Mar. 31, 2024
$ / shares
Mar. 31, 2024
EUR (€)
shares
Mar. 31, 2024
USD ($)
shares
Dec. 31, 2023
EUR (€)
Dec. 31, 2023
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2022
EUR (€)
Dec. 31, 2022
USD ($)
Feb. 17, 2022
EUR (€)
Dec. 31, 2021
USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]                      
Cash and restricted cash       $ 4,191   $ 4,385 $ 5,056   $ 9,537   $ 37,616
Financial assets and liabilities           400     100    
Description of exchange rate then changing the rate by 10%. Management determined 10% is a 'reasonably possible' change in foreign currency rates by considering the approximate change in rates in the prior twelve months.                    
Cash       $ 4,200   4,400          
Cash flow model, high rate     25.10% 25.10%              
Expected shares to be issued | shares     632,484 632,484              
Cash flow model, low rate     18.40% 18.40%              
Closing share price | $ / shares   $ 2.31                  
Credit risk [Member]                      
Derivative Instruments and Hedging Activities Disclosures [Line Items]                      
Cash and restricted cash           4,400     8,900    
Credit risk [Member] | Held with large financial institutions and national central banks [Member]                      
Derivative Instruments and Hedging Activities Disclosures [Line Items]                      
Cash and restricted cash           4,400     8,900    
Credit risk [Member] | Held with financial intermediaries [Member]                      
Derivative Instruments and Hedging Activities Disclosures [Line Items]                      
Cash and restricted cash           100     $ 100    
German subsidiaries [Member]                      
Derivative Instruments and Hedging Activities Disclosures [Line Items]                      
Available credit facilities         € 2,200,000 $ 2,400          
TruHC Pharma GmbH [Member]                      
Derivative Instruments and Hedging Activities Disclosures [Line Items]                      
Cash and restricted cash | € € 3,551   € 13,899   13,588     € 15,281   € 0  
Cash | €     13,899   13,588     15,281      
Fair value of debt | €     € 577,354   € 504,264     € 228,704